Coya Therapeutics, Inc.
COYACoya Therapeutics, Inc. in brief
Coya Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Houston, Texas, USA. Its market value was $92 M on 26 October 2026, which makes it the 19,017th largest listed company in the world and the 3,552nd largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $21 M. Its shares trade under the symbol COYA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Coya Therapeutics, Inc.
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr. Shimon Sakaguchi and since their discovery multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Dr. Sakaguchi was the 2025 winner of the Nobel Prize in Physiology or Medicine. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals. Dysfunctional Tregs underlie numerous disease states, and this cellular dysfunction is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. Further, the degree of Treg dysfunction is correlated with the severity and progression of serious and life-threatening conditions. These and other recent advances in the understanding of Treg biology, have made this subset of T-lymphocytes an important potential therapeutic target, which we believe may provide new treatments for serious diseases.
From the company's annual report filed with the US SEC: read the report
Coya Therapeutics, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 🔔Initial public offeringFinal prospectus filed with the SEC on 30 December 2022; shares registered for exchange trading on 27 December 2022.
- 2025
- 💰Record revenue of $8 millionFY2025, the highest of the 3 years on record.
Events of Coya Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,436 (Oct 2026) · #3,556 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 19.7×
- Price / book
- 2.1×
- Free cash flow yield
- —
- Net margin (TTM)
- -643.5%
- Operating margin
- -283.8%
- Return on equity
- -70.1%
- Liabilities / assets
- 13.9%
- Revenue growth
- +123.9%
- R&D / revenue
- 210.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $8M | +123.9% | $-23M | $-21M | -267.0% |
| Dec 2024 | $4M | -40.8% | $-17M | $-15M | -419.2% |
| Dec 2023 | $6M | — | $-8M | $-8M | -133.2% |
| Dec 2022 | — | — | $-10M | $-12M | — |
| Dec 2021 | — | — | $-5M | $-5M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | — | — | $-1.27 | — |
| Dec 2024 | $-10M | — | — | $-0.98 | — |
| Dec 2023 | $-11M | — | — | $-0.79 | — |
| Dec 2022 | $-7M | — | — | $-4.73 | — |
| Dec 2021 | $-4M | — | — | $-1.89 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (-93.5% on a year earlier), net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 14, 20268-KCurrent reportOther events
- Oct 5, 20268-KCurrent reportOther events
- Sep 15, 20268-KCurrent reportOther events
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Aug 7, 20268-K/ACurrent report (amended)Directors or officers changed
- Jun 25, 20268-KCurrent reportShareholder vote
- May 13, 2026DEF 14AProxy statement
- May 12, 20268-KCurrent reportMaterial agreement
- May 12, 202610-QQuarterly report · period to Mar 2026
Official filings of Coya Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $8 M
- Operating income
- $-23 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $50 M
- Total liabilities
- $7 M
- Total equity
- $43 M
As of December-2025
Top 52 institutional investors in Coya Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | DME Capital Management, LP | 2,335,540 | 0 (0.00%) | 9.96% | $12 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 852,751 | +10,531 (+1.25%) | 3.64% | $4 M | Nov 13, 2026 |
| 3 | AIGH Capital Management LLC | 631,912 | 0 (0.00%) | 2.69% | $3 M | Nov 2, 2026 |
| 4 | Alyeska Investment Group, L.P. | 400,000 | -400,000 (-50.00%) | 1.71% | $2 M | Nov 16, 2026 |
| 5 | CM Management, LLC | 400,000 | 0 (0.00%) | 1.71% | $2 M | Nov 12, 2026 |
| 6 | Private Management Group Inc | 380,876 | -3,341 (-0.87%) | 1.62% | $2 M | Nov 4, 2026 |
| 7 | Marshall Wace, LLP | 323,849 | +74,056 (+29.65%) | 1.38% | $2 M | Nov 13, 2026 |
| 8 | Prosight Management, LP | 229,600 | +59,600 (+35.06%) | 0.98% | $1 M | Nov 13, 2026 |
| 9 | Geode Capital Management, LLC | 211,036 | -17,207 (-7.54%) | 0.90% | $1 M | Nov 6, 2026 |
| 10 | Dimensional Fund Advisors LP | 169,458 | +13,541 (+8.68%) | 0.72% | $1 M | Nov 4, 2026 |
| 11 | Vanguard Fiduciary Trust Co | 129,551 | 0 (0.00%) | 0.55% | $1 M | Nov 13, 2026 |
| 12 | Renaissance Technologies LLC | 121,800 | -71,186 (-36.89%) | 0.52% | $1 M | Nov 12, 2026 |
| 13 | Prelude Capital Management, LLC | 101,885 | +555 (+0.55%) | 0.43% | $1 M | Nov 16, 2026 |
| 14 | Jones Financial Companies Lllp | 100,160 | -10,750 (-9.69%) | 0.43% | $1 M | Nov 13, 2026 |
| 15 | JBF Capital, Inc. | 100,006 | 0 (0.00%) | 0.43% | $1 M | Nov 16, 2026 |
| 16 | BlackRock, Inc. | 98,596 | -3,812 (-3.72%) | 0.42% | $0 M | Nov 13, 2026 |
| 17 | Royal Bank Of Canada | 83,900 | -9,514 (-10.18%) | 0.36% | $0 M | Nov 16, 2026 |
| 18 | State Street Corp | 79,813 | 0 (0.00%) | 0.34% | $0 M | Nov 12, 2026 |
| 19 | Prudential Financial Inc | 79,701 | New | 0.34% | $0 M | Nov 16, 2026 |
| 20 | Morgan Stanley | 77,700 | -4,406 (-5.37%) | 0.33% | $0 M | Nov 13, 2026 |
| 21 | Susquehanna International Group, LLP | 64,144 | +3,138 (+5.14%) | 0.27% | $0 M | Nov 16, 2026 |
| 22 | Goldman Sachs Group Inc | 46,421 | +20,241 (+77.31%) | 0.20% | $0 M | Nov 16, 2026 |
| 23 | Northern Trust Corp | 45,072 | 0 (0.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 24 | ADAR1 Capital Management, LLC | 40,900 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 25 | Long Corridor Asset Management Ltd | 38,766 | 0 (0.00%) | 0.17% | $0 M | Nov 12, 2026 |
Show all 52: investors 26 to 52
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | UBS Group AG | 34,495 | +1,407 (+4.25%) | 0.15% | $0 M | Nov 10, 2026 |
| 27 | Jane Street Group, LLC | 28,495 | New | 0.12% | $0 M | Nov 12, 2026 |
| 28 | GHP Investment Advisors, Inc. | 26,171 | 0 (0.00%) | 0.11% | $0 M | Oct 15, 2026 |
| 29 | XTX Topco Ltd | 21,102 | -20,299 (-49.03%) | 0.09% | $0 M | Nov 16, 2026 |
| 30 | Northwestern Mutual Wealth Management Co | 20,626 | 0 (0.00%) | 0.09% | $0 M | Nov 13, 2026 |
| 31 | Axq Capital, LP | 15,927 | -3,882 (-19.60%) | 0.07% | $0 M | Nov 12, 2026 |
| 32 | Mercer Global Advisors Inc /adv | 12,320 | New | 0.05% | $0 M | Nov 16, 2026 |
| 33 | American Century Companies Inc | 11,218 | New | 0.05% | $0 M | Nov 12, 2026 |
| 34 | Raymond James Financial Inc | 10,225 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 35 | HighTower Advisors, LLC | 10,029 | 0 (0.00%) | 0.04% | $0 M | Nov 10, 2026 |
| 36 | Charles Schwab Investment Management Inc | 10,000 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 37 | First Dallas Securities Inc. | 10,000 | New | 0.04% | $0 M | Nov 13, 2026 |
| 38 | Vanguard Global Advisers, LLC | 5,879 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 39 | Jpmorgan Chase & Co | 5,004 | -177 (-3.42%) | 0.02% | $0 M | Nov 12, 2026 |
| 40 | BNP Paribas Financial Markets | 4,763 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 41 | Bfsg, LLC | 3,455 | 0 (0.00%) | 0.01% | $0 M | Oct 30, 2026 |
| 42 | Tower Research Capital LLC (TRC) | 3,217 | New | 0.01% | $0 M | Nov 16, 2026 |
| 43 | Rockefeller Capital Management L.P. | 2,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 44 | Allworth Financial LP | 1,000 | -12,000 (-92.31%) | 0.00% | $0 M | Nov 17, 2026 |
| 45 | SBI Securities Co., Ltd. | 820 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 46 | Wells Fargo & Company/mn | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 47 | North Star Investment Management Corp. | 340 | 0 (0.00%) | 0.00% | $0 M | Oct 27, 2026 |
| 48 | Superior Planning, LLC | 315 | — | 0.00% | $0 M | Nov 12, 2026 |
| 49 | Arax Advisory Partners | 190 | +130 (+216.67%) | 0.00% | $0 M | Nov 12, 2026 |
| 50 | Triumph Capital Management | 50 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 51 | Caitong International Asset Management Co., Ltd | 35 | -6 (-14.63%) | 0.00% | $0 M | Oct 29, 2026 |
| 52 | Barclays PLC | 3 | -110 (-97.35%) | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Coya Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 601,117 | $4 M | 2.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 219,955 | $1 M | 0.94% | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 108,636 | $1 M | 0.46% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 65,909 | $0 M | 0.28% | 0.03% | +39% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 75,558 | $0 M | 0.32% | <0.01% | +0.6% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 33,438 | $0 M | 0.14% | <0.01% | +41% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 37,158 | $0 M | 0.16% | <0.01% | +148% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 24,066 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 14,892 | $0 M | 0.06% | <0.01% | +86% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 10,902 | $0 M | 0.05% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 10,246 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 13,107 | $0 M | 0.06% | <0.01% | +6.5% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 10,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 4,435 | $0 M | 0.02% | 0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 4,793 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 3,506 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 3,494 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 2,845 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 2,312 | $0 M | <0.01% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 1,977 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 1,715 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 137 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 22 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Coya Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Dov A. GoldsteinDirector | Option exercise | +17,557 | $1.090 | $19 K | 27,557 | Form 4 |
| filed | David S. SnyderChief Financial Officer | Buy | +1,800 | $7.190 | $13 K | 8,800 | Form 4 |
| filed | Arun SwaminathanChief Executive Officer, Director | Buy | +5,000 | $7.360 | $37 K | 10,000 | Form 4 |
| filed | Fred GrossmanChief Medical Officer | Buy | +2,710 | $7.370 | $20 K | 2,710 | Form 4 |
| filed | Arun SwaminathanChief Executive Officer, Director | Buy | +5,000 | $7.340 | $37 K | 5,000 | Form 4 |
| filed | Ann LeeDirector | Buyindirect | +1,000 | $3.620 | $4 K | 17,479 | Form 4 |
| filed | Adrian HepnerChief Medical Officer | Buy | +10,000 | — | — | 10,000 | Form 4 |
| filed | Hideki GarrenDirector | Buy | +2,000 | — | — | 2,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Coya Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-5.69 reverse split
Fails to deliver
- : 2,731 shares at $3.94
- : 190 shares at $4.25
- : 80 shares at $4.81
- : 617 shares at $5.18
- : 5,020 shares at $5.04
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Coya Therapeutics, Inc. scorecard#
Passes 4 of the 14 checks that could be worked out: strongest in financial health (2 of 3), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.1×Price to book 2.1× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median19.7×Price to sales 19.7× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- ✓Revenue grew in the newest year123.9%Revenue up 123.9% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.27 vs -0.98Diluted EPS -1.27 in fiscal 2025 against -0.98 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-283.8%-283.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-51.4%-51.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities8.5×Current ratio 8.51 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone6.00Z-score 6.00 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year9.8%Diluted shares up 9.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Coya Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -283.8% | -60.5% | |
| Net margin | -267.0% | -68.9% | |
| Return on equity | -51.4% | -61.0% | |
| Revenue growth | 123.9% | 15.8% |
2of 7on the Piotroski tests of financial strength
- Net loss of $21 million, the 5th loss-making year in a row.
- The share count rose 9.8% in the year.
Coya Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 7,946+124%100% | 3,554−40.8%100% | 6,002—100% | 0—— | — | |
| Research and development | 16,735+41.0%211% | 11,866+116%334% | 5,502+24.7%91.7% | 4,412+73.6%— | 2,542—— | |
| General and administrative | 11,449+28.9%144% | 8,886+13.4%250% | 7,833+61.6%131% | 4,847+110%— | 2,312—— | |
| Operating expenses | 30,501+46.6%384% | 20,804+49.6%585% | 13,906+41.7%232% | 9,812+101%— | 4,870—— | |
| Operating income | −22,555—−284% | −17,250—−485% | −7,903—−132% | −9,812—— | −4,870—— | |
| Other non-operating income (expense) | 1,332−19.2%16.8% | 1,649+158%46.4% | 639+904%10.7% | 64—— | −21—— | |
| Income before tax | −21,223—−267% | −15,601—−439% | −7,264—−121% | −12,245—— | — | |
| Income tax | 3.1—0.0% | −720−200%−20.3% | 724—12.1% | 0—— | — | |
| Net income including minority interests | −21,226—−267% | −14,881—−419% | −7,988—−133% | −12,245—— | −4,892—— | |
| Net income attributable to shareholders | −21,226—−267% | −14,881—−419% | −7,988—−133% | −12,245—— | −4,892—— | |
| Earnings per share, basic | -1.27—— | -0.98—— | -0.79—— | -4.73—— | -1.89—— | |
| Earnings per share, diluted | -1.27—— | -0.98—— | -0.79—— | -4.73—— | -1.89—— | |
| Shares, weighted average (basic) | 17+9.8%— | 15+49.9%— | 10+292%— | 2.6+0.0%— | 2.6—— | |
| Shares, weighted average (diluted) | 17+9.8%— | 15+49.9%— | 10+292%— | 2.6+0.0%— | 2.6—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 46,823+22.1%93.7% | 38,340+17.5%86.5% | 32,627+450%79.1% | 5,934+36.7%70.7% | 4,340—90.6% | |
| Other current assets | 3,116−47.8%6.2% | 5,969+458%13.5% | 1,070−14.5%2.6% | 1,251+413%14.9% | 244—5.1% | |
| Current assets | 49,939+12.7%100.0% | 44,308+7.6%99.9% | 41,196+473%99.8% | 7,185+56.7%85.6% | 4,584—95.7% | |
| Property, plant and equipment | 11−70.9%0.0% | 39−41.5%0.1% | 66−29.3%0.2% | 93−22.7%1.1% | 121—2.5% | |
| Total assets | 49,950+12.6%100% | 44,347+7.5%100% | 41,262+391%100% | 8,396+75.2%100% | 4,792—100% | |
| Accounts payable | 1,061−33.2%2.1% | 1,588+37.4%3.6% | 1,156−36.3%2.8% | 1,815+112%21.6% | 858—17.9% | |
| Current liabilities | 5,872+53.5%11.8% | 3,824−24.3%8.6% | 5,052+32.1%12.2% | 3,824+233%45.5% | 1,148—24.0% | |
| Total liabilities | 6,922+45.1%13.9% | 4,770−15.2%10.8% | 5,627−66.5%13.6% | 16,789+1362%200% | 1,148—24.0% | |
| Retained earnings | −61,963—−124% | −40,737—−91.9% | −25,856—−62.7% | −17,869—−213% | −5,624—−117% | |
| Shareholders' equity | 43,028+8.7%86.1% | 39,577+11.1%89.2% | 35,636—86.4% | −8,394−330%−100.0% | 3,644—76.0% | |
| Total liabilities and equity | 49,950+12.6%100% | 44,347+7.5%100% | 41,262+391%100% | 8,396+75.2%100% | 4,792—100% | |
| Shares outstanding | 21+25.3%— | 17+16.0%— | 14+456%— | 2.6r2.6+0.0%— | 2.6—— | |
| Cash-flow statement | ||||||
| Share-based compensation | 4,290+61.1%54.0% | 2,664+205%74.9% | 872+321%14.5% | 207−11.1%— | 233—— | |
| Cash from operating activities | −10,739—−135% | −10,289—−289% | −11,189—−186% | −7,239—— | −3,903—— | |
| Cash from investing activities | −1,165—−14.7% | −25—−0.7% | −543—−9.0% | −525—— | −137—— | |
| Shares issued | 20,349+45.3%256% | 14,004—394% | — | — | — | |
| Cash from financing activities | 20,387+27.2%257% | 16,027−58.3%451% | 38,425+311%640% | 9,358—— | −341—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 4,689+17.6%100% | 234−93.4%100% | 244+49.0%100% | 251−2.6%100% | 3,960*+202769%100% | 3,564—100% | 164−95.2%100% | 258+103%100% | 2.0*−100.0%100% | 0—— | 3,425—100% | 127—100% | 6,002*—100% | |
| Research and development | 22,639+64.9%483% | 8,571+194%3661% | 5,031+37.3%2064% | 4,097−21.4%1631% | 4,940*+155%125% | 2,917+31.2%81.8% | 3,663−19.8%2239% | 5,214+66.2%2022% | 1,937*+20.4%99254% | 2,224—— | 4,566—133% | 3,138—2474% | 1,610*—26.8% | |
| General and administrative | 11,893+15.3%254% | 2,586+1.1%1104% | 2,256−22.4%925% | 3,782+39.4%1506% | 3,270*+52.9%82.6% | 2,557+15.2%71.8% | 2,908+39.3%1777% | 2,714+11.2%1052% | 2,138*−10.1%109527% | 2,220—— | 2,088—61.0% | 2,440—1924% | 2,377*—39.6% | |
| Operating expenses | 36,356+47.8%775% | 11,183+86.5%4776% | 7,291+10.8%2991% | 7,891−0.5%3142% | 9,991*+145%252% | 5,997+34.8%168% | 6,578−1.2%4020% | 7,935+41.4%3077% | 4,082*−2.5%209132% | 4,450—— | 6,661—194% | 5,610—4423% | 4,187*—69.8% | |
| Operating income | −31,667—−675% | −10,949—−4676% | −7,047—−2891% | −7,640—−3042% | −6,031*—−152% | −2,433—−68.3% | −6,415—−3920% | −7,677—−2977% | −4,080*−325%−209032% | −4,450—— | −3,236—−94.5% | −5,483—−4323% | 1,815*—30.2% | |
| Other non-operating income (expense) | 1,498+3.3%32.0% | 331+4.4%141% | 409+27.9%168% | 433+17.0%172% | 325*−26.7%8.2% | 317−26.1%8.9% | 320−7.2%195% | 370−14.1%144% | 444*+154%22758% | 429—— | 344—10.1% | 431—340% | 175*—2.9% | |
| Income before tax | −30,168—−643% | −10,618—−4535% | −6,638—−2723% | −7,207—−2870% | −5,705*—−144% | −2,116—−59.4% | −6,095—−3725% | −7,307—−2833% | — | — | −2,892—−84.4% | −5,052—−3983% | — | |
| Income tax | — | — | — | — | — | — | 0—0.0% | — | — | — | 0—0.0% | — | — | |
| Net income including minority interests | −30,172—−643% | −10,618*—−4535% | −6,638*—−2723% | −7,207—−2870% | −5,709*—−144% | −2,116*—−59.4% | −6,095*—−3725% | −7,307—−2833% | −2,916*−330%−149374% | −4,021*—— | −2,892*—−84.4% | −5,052—−3983% | 1,266*—21.1% | |
| Net income attributable to shareholders | −30,172—−643% | −10,618—−4535% | −6,638—−2723% | −7,207—−2870% | −5,709*—−144% | −2,116—−59.4% | −6,095—−3725% | −7,307—−2833% | −2,916*−330%−149374% | −4,021—— | −2,892—−84.4% | −5,052—−3983% | 1,266*—21.1% | |
| Earnings per share, basic | — | -0.45—— | -0.28—— | -0.32—— | — | -0.13—— | -0.36—— | -0.44—— | — | -0.26—— | -0.19—— | -0.35—— | — | |
| Earnings per share, diluted | — | -0.45—— | -0.28—— | -0.32—— | — | -0.13—— | -0.36—— | -0.44—— | — | -0.26—— | -0.19—— | -0.35—— | — | |
| Shares, weighted average (basic) | 23+40.2%— | 23+40.2%— | 23+40.3%— | 23+35.4%— | — | 17+9.9%— | 17+12.1%— | 17+15.7%— | — | 15—— | 15—— | 14—— | — | |
| Shares, weighted average (diluted) | 23+40.2%— | 23+40.2%— | 23+40.3%— | 23+35.4%— | — | 17+9.9%— | 17+12.1%— | 17+15.7%— | — | 15—— | 15—— | 14—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 35,802—91.1% | 35,802+27.3%91.1% | 43,181+45.1%91.3% | 50,725+42.8%95.2% | 46,823+22.1%93.7% | 28,130−9.4%87.8% | 29,757−18.6%89.0% | 35,531−1.3%92.5% | 38,340+17.5%86.5% | 31,057—87.4% | 36,575—91.6% | 35,989—96.2% | 32,627—79.1% | |
| Other current assets | 3,268—8.3% | 3,268−16.1%8.3% | 3,877+5.6%8.2% | 2,538−10.7%4.8% | 3,116−47.8%6.2% | 3,895−12.5%12.2% | 3,670+10.8%11.0% | 2,843+111%7.4% | 5,969+458%13.5% | 4,449—12.5% | 3,311—8.3% | 1,345—3.6% | 1,070—2.6% | |
| Current assets | 39,070—99.4% | 39,070+22.0%99.4% | 47,058+40.8%99.5% | 53,263+38.8%100.0% | 49,939+12.7%100.0% | 32,025−9.8%99.9% | 33,428−16.2%99.9% | 38,373+2.8%99.9% | 44,308+7.6%99.9% | 35,506—99.9% | 39,886—99.9% | 37,334—99.8% | 41,196—99.8% | |
| Property, plant and equipment | 2.8—0.0% | 2.8−84.5%0.0% | 5.6−77.5%0.0% | 8.4−73.5%0.0% | 11−70.9%0.0% | 18−60.2%0.1% | 25−52.3%0.1% | 32−46.3%0.1% | 39−41.5%0.1% | 45—0.1% | 52—0.1% | 59—0.2% | 66—0.2% | |
| Total assets | 39,318—100% | 39,318+22.7%100% | 47,308+41.4%100% | 53,271+38.7%100% | 49,950+12.6%100% | 32,043−9.9%100% | 33,453−16.2%100% | 38,405+2.7%100% | 44,347+7.5%100% | 35,552—100% | 39,939—100% | 37,393—100% | 41,262—100% | |
| Accounts payable | 2,452—6.2% | 2,452+121%6.2% | 1,086+16.6%2.3% | 948−43.9%1.8% | 1,061−33.2%2.1% | 1,112+230%3.5% | 931−50.5%2.8% | 1,690+6.4%4.4% | 1,588+37.4%3.6% | 337—0.9% | 1,883—4.7% | 1,588—4.2% | 1,156—2.8% | |
| Current liabilities | 5,395—13.7% | 5,395+47.1%13.7% | 3,512−22.0%7.4% | 3,547−18.3%6.7% | 5,872+53.5%11.8% | 3,667+58.1%11.4% | 4,501+17.7%13.5% | 4,341+0.5%11.3% | 3,824−24.3%8.6% | 2,319—6.5% | 3,825—9.6% | 4,319—11.6% | 5,052—12.2% | |
| Total liabilities | 5,749—14.6% | 5,749+20.8%14.6% | 4,032−21.6%8.5% | 4,301−14.6%8.1% | 6,922+45.1%13.9% | 4,758+34.4%14.9% | 5,142+9.8%15.4% | 5,035+0.7%13.1% | 4,770−15.2%10.8% | 3,542—10.0% | 4,682—11.7% | 5,000—13.4% | 5,627—13.6% | |
| Retained earnings | −86,426—−220% | −86,426—−220% | −75,809—−160% | −69,170—−130% | −61,963—−124% | −56,255—−176% | −54,139—−162% | −48,044—−125% | −40,737—−91.9% | −37,821—−106% | −33,800—−84.6% | −30,908—−82.7% | −25,856—−62.7% | |
| Shareholders' equity | 33,568—85.4% | 33,568+23.0%85.4% | 43,276+52.9%91.5% | 48,970+46.8%91.9% | 43,028+8.7%86.1% | 27,284−14.8%85.1% | 28,310−19.7%84.6% | 33,370+3.0%86.9% | 39,577+11.1%89.2% | 32,010—90.0% | 35,257—88.3% | 32,393—86.6% | 35,636—86.4% | |
| Total liabilities and equity | 39,318—100% | 39,318+22.7%100% | 47,308+41.4%100% | 53,271+38.7%100% | 49,950+12.6%100% | 32,043−9.9%100% | 33,453−16.2%100% | 38,405+2.7%100% | 44,347+7.5%100% | 35,552—100% | 39,939—100% | 37,393—100% | 41,262—100% | |
| Shares outstanding | 23—— | 23+40.1%— | 23+40.3%— | 23+40.3%— | 21+25.3%— | 17+10.0%— | 17+9.9%— | 17+14.5%— | 17+16.0%— | 15—— | 15—— | 15—— | 14—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5,153+29.6%110% | 910−15.0%389% | 944−8.9%387% | 2,196+103%874% | 1,104*+39.6%27.9% | 1,071+38.2%30.0% | 1,036+56.4%633% | 1,080+148%419% | 791*+232%40499% | 775—— | 662—19.3% | 436—343% | 238*—4.0% | |
| Cash from operating activities | −21,827—−465% | −7,235*—−3090% | −7,376*—−3026% | −6,209—−2472% | −1,007*—−25.4% | −1,131*—−31.7% | −5,773*—−3529% | −2,828−232%−1097% | −2,410*—−123451% | −5,461*—— | −4,564*—−133% | 2,146—1692% | −2,241*—−37.3% | |
| Cash from investing activities | −1,559—−33.2% | −23*—−9.9% | −1.7*—−0.7% | −885—−352% | −649*—−16.4% | — | — | — | 0*—0.0% | 0*—— | 0*—0.0% | −25—−19.7% | −193*—−3.2% | |
| Shares issued | — | 0*—0.0% | −42*—−17.1% | 10,995—4378% | — | — | — | — | 9,061*—464176% | −56*—— | — | — | — | |
| Cash from financing activities | 31,058+219%662% | −120*−729%−51.4% | −166*—−68.1% | 10,995+57356%4378% | 20,349*+110%514% | 19*—0.5% | 0*−100%0.0% | 19−98.5%7.4% | 9,692*−59.9%496523% | −56*—— | 5,149*—150% | 1,242—979% | 24,175*—403% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Coya Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 3 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2024 | $10 M | Private placement after listing | $10 to $50 million | 9 | equity | SEC |
| Dec 2023 | $26 M | Private placement after listing | $10 to $50 million | 122 | equity, options | SEC |
| Apr 2022 | $10 M | No. 2 | $10 to $50 million | 45 | debt, options | SEC |
| Dec 2020 | $10 M | No. 1 | $10 to $50 million | 57 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Coya Therapeutics, Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2022, most often on budget/appropriations and medical/disease research/clinical labs.
- Budget/Appropriations2 reports
- Medical/Disease Research/Clinical Labs2 reports
Lobbying firms hired in 2022
Winning Strategies Washington $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $20 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Coya Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Coya Therapeutics, Inc. compares in Biotechnology
- Market cap$92 M · higher than 35% of 726
- Revenue$8 M · higher than 41% of 647
- Net margin-643.5% · higher than 7% of 408
- Revenue growth123.9% · higher than 85% of 438
- Price / sales19.7× · lower than 32% of 339
- Price / book2.1× · lower than 56% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Coya Therapeutics, Inc.🇺🇸 | $92 M | — | -643.5% | +123.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Coya Therapeutics, Inc.? Verify and update this profile — free
Show Coya Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.